An interventional study of Stannous Fluoride and Sodium Monofluorophosphate in Gingivitis, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-26.
Sponsored by GlaxoSmithKline · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing Tin Fluorides in Gingivitis — 1 open to participants now, 3 under way, none of them phase 3. Tin Fluorides · Gingivitis.
Among the 23 studies testing Tin Fluorides in Gingivitis, this one is the 3rd largest by enrollment, is one of 3 that started in 2015, is one of 10 with no phase, and was the 7th registered.
631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.
Browse Gingivitis studies →1 of the 23 studies testing Tin Fluorides in Gingivitis is open now. Recruiting first, the newest first:
Colgate Palmolive
Ages 60+ · Healthy volunteers
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2015.
This study's enrollment of 253 is above the median of 66 across 507 interventional studies indexed under Gingivitis.
Median enrollment 115 across the 23 interventional studies. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 23 have an industry lead sponsor. The 6 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 8 studies filed under Gingivitis — fewer than ten, so there is no comparison to draw.
1 of the studies testing Tin Fluorides in Gingivitis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07807397Colgate PalmoliveOral Hygiene Assistance Training Program | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing Tin Fluorides in Gingivitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This will be a single-center, 12 week, examiner-blind, randomized, stratified (gender and baseline mean whole mouth MGI score), two-treatment, parallel group, clinical study in healthy adult volunteers with moderate gingivitis. This study will evaluate the efficacy of a dentifrice containing 0.454% weight by weight (w/w) stannous fluoride to control gingivitis and gingival bleeding following 12 weeks twice daily brushing, compared to a negative control dentifrice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ii. Currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
iii. Currently taking a systemic medication which, in the opinion of the C. Baseline, Day 28 and Day 96 Assessment Visits i. Has taken antibiotics in the previous 14 days. ii. Has taken an anti-inflammatory medication which, in the opinion of the investigator, could affect gingival condition in the previous 14 days.
iii. Has taken a systemic medication which, in the opinion of the investigator, could affect gingival condition in the previous 14 days (e.g. calcium channel blockers, or aspirin therapy).could affect gingival condition in the previous 14 days (e.g. calcium channel blockers, or aspirin therapy).Investigator, could affect gingival condition (e.g. calcium channel blockers, or aspirin therapy).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will apply a full ribbon of dentifrice containing 0.454% w/w stannous fluoride to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
Drug: Stannous Fluoride
Participants will apply a full ribbon of dentifrice containing Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
Drug: Sodium Monofluorophosphate
Dentifrice containing 0.454% w/w stannous fluoride
Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
Number of Bleeding Sites at Week 12
Number of bleeding sites was measured as bleeding index (BI) via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth (7-7 in each arch). The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. Bleeding sites were assessed as the number of bleeding sites with a BI score of 1 or 2.
Time frame: Week 12
Number of Bleeding Sites at Week 4
Number of bleeding sites was measured as BI via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth (7-7 in each arch). The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. Bleeding sites were assessed as the number of bleeding sites with a BI score of 1 or 2.
Time frame: Week 4
Bleeding Index (BI) at Week 4 and Week 12
BI was assessed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system to be used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
Time frame: Week 4, Week 12
Modified Gingival Index (MGI) at Week 4 and Week 12
MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration.
Time frame: Week 4, Week 12
Number of Participants With Visible Blood in Expectorate (Presence [Trace, Substantial]/Absence) at Week4 and Week 12
Visible blood in expectorate for each participant was classified as (i) Present (Trace or Substantial) (ii) Absent. The number of participants with blood 'Present' (Trace or Substantial) or 'absent' in expectorate was analyzed.
Time frame: Week 4, Week 12
Participants were recruited in a single center in Germany.
| Milestone | Stannous Fluoride | Sodium Monofluorophosphate |
|---|---|---|
| Started | 125 | 128 |
| Completed | 119 | 119 |
| Not completed | 6 | 9 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Withdrawal by subject | 5 | 7 |
Number of bleeding sites was measured as bleeding index (BI) via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth (7-7 in each arch). The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. Bleeding sites were assessed as the number of bleeding sites with a BI score of 1 or 2.
| number of bleeding sites | Stannous Fluoride | Sodium Monofluorophosphate |
|---|---|---|
| Number of Bleeding Sites at Week 12 | 42.02 ± 1.91 | 67.36 ± 1.91 |
Number of bleeding sites was measured as BI via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth (7-7 in each arch). The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. Bleeding sites were assessed as the number of bleeding sites with a BI score of 1 or 2.
| number of bleeding sites | Stannous Fluoride | Sodium Monofluorophosphate |
|---|---|---|
| Number of Bleeding Sites at Week 4 | 45.44 ± 1.92 | 68.30 ± 1.91 |
BI was assessed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system to be used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
| score on a scale | Stannous Fluoride | Sodium Monofluorophosphate |
|---|---|---|
| BI at Week 4 (n=121, 122) | 0.29 ± 0.01 | 0.44 ± 0.01 |
| BI at Week 12 (n=119, 119) | 0.27 ± 0.01 | 0.43 ± 0.01 |
MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration.
| score on a scale | Stannous Fluoride | Sodium Monofluorophosphate |
|---|---|---|
| MGI at Week 4 | 2.27 ± 0.01 | 2.40 ± 0.01 |
| MGI at Week 12 | 2.29 ± 0.01 | 2.47 ± 0.01 |
Visible blood in expectorate for each participant was classified as (i) Present (Trace or Substantial) (ii) Absent. The number of participants with blood 'Present' (Trace or Substantial) or 'absent' in expectorate was analyzed.
| number of participants | Stannous Fluoride | Sodium Monofluorophosphate |
|---|---|---|
| At Week 4, Visible blood= Present | 92 | 89 |
| At Week 4, Visible blood= Trace | 35 | 31 |
| At Week 4, Visible blood= Substantial | 57 | 58 |
| At Week 4, Visible blood= Absent | 30 | 34 |
| At Week 12, Visible blood= Present | 72 | 78 |
| At Week 12, Visible blood= Trace | 18 | 13 |
| At Week 12, Visible blood= Substantial | 54 | 65 |
| At Week 12, Visible blood= Absent | 47 | 41 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stannous Fluoride | — | 0/125 (0%) | 20/125 (16%) |
| Sodium Monofluorophosphate | — | 0/128 (0%) | 22/128 (17.2%) |
| Event | Stannous Fluoride | Sodium Monofluorophosphate |
|---|---|---|
| Oral hyperkeratosisGastrointestinal disorders | 15/125 | 19/128 |
| Gingival painGastrointestinal disorders | 2/125 | 0/128 |
| Gingival injuryInjury, poisoning and procedural complications | 1/125 | 0/128 |
| NasopharyngitisInfections and infestations | 1/125 | 0/128 |
| Oral herpesInfections and infestations | 1/125 | 0/128 |
| NauseaGastrointestinal disorders | 0/125 | 1/128 |
| Face InjuryInjury, poisoning and procedural complications | 0/125 | 1/128 |
| Head injuryInjury, poisoning and procedural complications | 0/125 | 1/128 |
| Neck injuryInjury, poisoning and procedural complications | 0/125 | 1/128 |
| Tooth fractureInjury, poisoning and procedural complications | 0/125 | 1/128 |
| Age, Continuous(Years) | Stannous Fluoride | Sodium Monofluorophosphate | Total |
|---|---|---|---|
| Mean | 39.39 ± 13.610 | 36.37 ± 13.179 | 37.86 ± 13.453 |
| Sex: Female, Male(Participants) | Stannous Fluoride | Sodium Monofluorophosphate | Total |
|---|---|---|---|
| Female | 71 | 73 | 144 |
| Male | 54 | 55 | 109 |
The record gives a start of Nov 2015, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tin Fluorides